Audit: QRS - Black Currant Oil for Health & Longevity
Audit conducted on 17/08/2026 06:09 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 83 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Verified item by item against the ER: protocol cells vs ER lines 348/350/356/360, time cells vs ER 358/403, benefit and risk items vs ER section headings, gate items vs ER 304-326, monitoring table vs ER 431-438, cadence vs ER 429, qualitative items vs ER 442-446. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Cautious ER phrasing retained, e.g. “No established target” (ER line 433) in [marker_1_target] and “Clinical payoff stays uncertain” from the ER Conclusion (line 474) in [at_a_glance]. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening detected; contraindication severity qualifiers (“below 50 × 10⁹/L”, “within 2 weeks”, “Uncontrolled seizure disorder”) carried across intact. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come only from the ER “Populations who should avoid Black Currant Oil” list; Key Interactions come only from the ER interaction bullets. No Benefit- or Risk-Modifying Factor was surfaced as a gate item. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PubMed IDs, author names, NCT identifiers or brand names appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind are present. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s measured, sceptical register (“evidence base is thin, old and small”, ER line 470). |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert and data-driven throughout, with concrete doses, windows and biomarker targets. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents protocols and trial-derived figures rather than instructing. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Phrasing is descriptive (“protocols split the dose”, “the international normalised ratio is checked”), not advisory. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Content is stated as observation, e.g. [action_2_sub] “No circadian rationale exists; absorption depends on bile flow and co-ingested fat.” |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the sheet. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms carried from the ER are necessary for fidelity; no gratuitous jargon added. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every cell is condensed to one or two clauses. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | No direct address; [marker_5_target] uses “the individual’s prescribed therapeutic window”. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Biomarker targets, genotype-relevant ratios and dose-escalation detail address a proactive, risk-aware reader. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Retains the 10,000 mg-of-oil inflammatory dose and the split-dosing regimen without softening the burden. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Assumes willingness to run fatty acid panels and international normalised ratio checks. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Weighs the intervention explicitly against marine omega-3 fats as a “narrow addition”, mirroring ER line 474. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | “Anti-aging” does not appear; ageing is framed via longevity relevance. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Uses “gastrointestinal upset”, “adverse”, “hypersensitivity”, “antihypertensives” rather than consumer-grade equivalents. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings, gate headings, tier labels and Monitoring column headers are byte-identical to the template. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | Diffed against [qrs_template]: all 34 named spans present, plus the repeatable marker_#* and qualitative_item# spans instantiated as marker_1..6 and qualitative_item_1..5. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The three website=”…” spans (evidence_review, audit, full_review), the style block, the override stylesheet link and the footer disclaimer are unchanged from the template. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section is empty; every ER section drawn on (Expected Benefits, Potential Risks & Side Effects, Key Interactions & Contraindications, Therapeutic Protocol, Monitoring Protocol & Defining Success) is populated, so no empty-state phrasing is required. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol cell labels reuse the ER bold labels verbatim: “Standard oral dose” (ER 348), “Timing” (ER 356), “Single versus split dosing” (ER 360). Gate items reuse the ER bold interaction labels. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Monitoring row labels are verbatim ER biomarker names; tier labels are template-fixed. Time-to-effect cell labels are unavoidably derived because the ER carries a single “Time to effect” bullet with no per-aspect labels. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji present; the ER’s 🟩/🟥/🟨 tier markers and ⚠️ Conflicted flags were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Section budgets respected: benefit and risk tiers are single lines, gates 5 and 8 short items, monitoring 6 rows, qualitative 5 items. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | HTML comment opens at line 2, immediately after “<!doctype html>” on line 1, and precedes the template comment and <html>. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” at line 3, closing “—” at line 13; the preceding “QRS — Metadata” text sits outside the block. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Contained entirely within the HTML comment; no metadata value is echoed by any rendered element. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed; only “00:03” is quoted, correctly, because it contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | “er_filename: black_currant_oil_2026-0825-0449_Opus_ER.md” matches the source ER on disk. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | “qrs_prompt_version: 26.7.02” matches the version badge of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | “qrs_creation_date: 2026-0817-0602” conforms to YYYY-MMDD-HHMM. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | “qrs_creator_ai_nickname: Opus” present. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | “qrs_creator_ai_fullname: Opus 5” present. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version number with no additional qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | “qrs_filename: black_currant_oil_2026-0825-0449_Opus_QRS.html” matches the actual filename. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified: no stray whitespace and no unnecessary quoting on any of the nine frontmatter values. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | [header_topic] is “Black Currant Oil for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | “08/17/2026” is qrs_creation_date 2026-0817 reformatted as MM/DD/YYYY. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | [header_subline_model] is “Opus 5”, matching qrs_creator_ai_fullname. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header carries only the title and the template subline; no badge, alternate-names line or audit stamp. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses the ER Conclusion (lines 468-474) into composition, the replicating biochemical finding, the class-inference caveat, the risk profile and the residual uncertainty. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 58 words, verified by word count. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to a distinct Conclusion passage: composition (line 468), biochemical replication (470), class inference (470), mild digestive risks (472), uncertain payoff (474). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Uses plain-language substitutes throughout — “an uncommon omega-6 fat” for gamma-linolenic acid, “one inflammatory signalling molecule” for prostaglandin E2, “blood chemistry” for the fatty acid panel. No acronyms. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial name, year, sample size or p-value appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect size, relative risk or statistical result appears. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from the “Populations who should avoid Black Currant Oil” list inside the ER Key Interactions & Contraindications section (ER lines 320-326). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All five ER avoid-populations are represented, one to one. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Each of the five items is a discrete <li> inside the [stop_items] span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | No rationale, citation or post-dash clause on any item; the ER gloss “(an inherited clotting-protein deficiency)” was correctly dropped. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Threshold and time-window qualifiers preserved: “below 50 × 10⁹/L”, “within 2 weeks, including dental extraction”, “Uncontrolled seizure disorder”, and the haemophilia / von Willebrand parenthetical. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER Key Interactions & Contraindications section uses no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The section is populated, and the ER does name populations that should avoid the oil, so the constraint holds. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The Contraindications section is not empty; it carries five items. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | Drawn from the eight interaction bullets of the ER Key Interactions & Contraindications section (ER lines 304-318). |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All eight ER interaction bullets are represented; none duplicates a Contraindication item. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Each of the eight items is a discrete <li> inside the [caution_items] span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Mechanistic rationale (“additive platelet inhibition”, “sesamin inhibits delta-5 desaturase”) and mitigation clauses stripped; no post-dash content remains. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Named example drug lists preserved for all six bullets that carry them, including the six-supplement list pulled forward from the ER body text of the “Other blood-pressure-lowering and platelet-inhibiting supplements” bullet. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER Key Interactions & Contraindications section uses no ranking notation inside parentheses. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The section is populated, and the ER does name interactions that change how the oil is used, so the constraint holds. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The Key Interactions section is not empty; it carries eight items. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells trace to the ER Therapeutic Protocol section (ER lines 348, 350, 356, 360). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, timing and single-versus-split dosing are the three execution-critical aspects; the remaining ER bullets are competing approaches, pharmacokinetics and modifier discussion. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Therapeutic Protocol section supplies more than three actionable implementation aspects; all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine label/value/sub fields carry ER-derived content; none is placeholder. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Blood fatty acid shift, joint symptoms and dry eye symptoms are three of the four aspects in the ER “Time to effect” bullet (ER line 403); the Low-tier immune response readout is the one omitted. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered High-tier benefit (dihomo-γ-linolenic acid enrichment) first, then the two Medium-tier benefits, with the Low-tier immune aspect dropped. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies four time-to-effect aspects; all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine label/value/sub fields carry ER-derived content, with sub-cells drawn from ER lines 358 and 403. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information (Practical Considerations, ER line 403), so the section is retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All four tiers trace to the ER Expected Benefits headings. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four benefit spans are present and populated. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items are the ER benefit headings alone; no magnitude, mechanism or trial detail carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content survives in any benefit item. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers carry items in the ER; no sub-section span needed hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All four tiers trace to the ER Potential Risks & Side Effects headings. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four risk spans are present and populated. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items are the ER risk headings alone; the “⚠️ Conflicted” flag, frequencies and relative risks are stripped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content survives in any risk item. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four risk tiers carry items in the ER; no sub-section span needed hiding. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | The six-row table reproduces the ER Monitoring Protocol & Defining Success biomarker table (ER lines 431-438). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All six ER biomarkers are listed with targets and rationales matching the ER text. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | [monitoring_cadence] reproduces the ER cadence paragraph (ER line 429), including the 12-week repeat, the 6-12 month interval and the anticoagulant international normalised ratio schedule. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | The five items reproduce the “Qualitative markers to track alongside the labs” list in the ER Monitoring Protocol & Defining Success section. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five ER qualitative markers are listed verbatim (ER lines 442-446). |
Issues 17/08/2026 06:09
Pass rate 100.00%. No issues found.